How to Participate in Our Studies

Are you a physician interested in referring patients to an existing site? Or would you like your site to participate in an ongoing or planned study?

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Programs in Alzheimer's and DLB:​

Download
our Vcard

Indication

Preclinical

Phase 1

Phase 2

Phase 3

SHINE (COG0201) Study

SHIMMER (COG1201) Study

START (COG0203) in Collaboration with the ACTC

Novel Approach

The σ-2 receptor is expressed by multiple cell types, including neuronal synapses in the brain and RPE, RGC and photoreceptors in the eye. The σ-2 complex is comprised of transmembrane protein 97 (TMEM97), a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1 (PGRMC1).

Human genetic and internal proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the σ-2 complex and dry AMD.

We believe that targeting the σ-2 complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of dry AMD.

Contact Cognition's Clinical Operations Team

Scroll to Top

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Thank you

Someone from the Cognition Therapeutics team
will be in touch with you soon.